Company intelligence / Profile preview

Arrive Bio

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Arrive Bio is an early-stage biotechnology company focused on developing next-generation RNA-based therapeutics. The company leverages a proprietary platform designed to improve the delivery and expression of RNA medicines, aiming to overcome current limitations in the field such as tissue specificity and durability of effect. Founded by industry veterans with experience in RNA interference and messenger RNA, Arrive Bio is positioning itself to address a broad range of diseases through optimized nucleic acid delivery systems. The company currently operates primarily in a stealth or early-development mode, focusing on refining its core technology and building an initial pipeline of candidates.

Modalities: RNA therapymRNA-based drugsLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Arrive Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arrive Bio.

Explore the full profile